{'fraction_non_alphanumeric': 0.029239766081871343, 'fraction_numerical': 0.015594541910331383, 'mean_word_length': 5.339506172839506, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
More on Persistent Endotheliopathy in the Pathogenesis of Long COVID Syndrome.

We are grateful for the comments and the interesting additional novel data presented by von Meijenfeldt et al [1]. These findings provide further evidence that sustained endotheliopathy and coagulopathy are both common in patients following acute COVID-19 [2-5]. The longitudinal data presented provide additional insights into the duration of specific aspects of COVID-19-induced hemostatic dysfunction. Previous studies have reported elevated D-dimer levels in 25% of patients in the first few months post-SARS-CoV-2 infection [2, 5]. Notwithstanding differences in patient cohorts and study design, von Meijenfeldt et al show that these elevated D-dimer levels after acute COVID appear to normalize by 4 months [1]. Given that convalescent COVID-19 patients commonly present with respiratory symptoms, this observation has important clinical implications with respect to the utility of D-dimer testing in pulmonary embolism testing algorithms.